




25. (NEW CLAIM)


A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis-inhibiting compound selected from the group consisting of the following compounds:




wherein R₁, R₂, R₃ and R₄ can be selected from: -H; -OH; =O, straight chained and branched alkanes, alkenes, alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XO_n or -O-XO_n, (where X=N and n=2; X=S and n=2 or 3; or X=P and n=1-3); and halogens; R₅, R₆, R₇, and R₈ are each independently selected from:




or -O- where Y is optional and is the same as defined above for R₁; and R₁₀ is the same as defined above for R₁, or (where Y is absent) R₁₀ is =O; and R₉ is a moiety having formula A) or B):



where each of R₁₁ - R₁₇ is independently the same as defined above for R₅;




where R₁₈, R₁₉ and R₂₀ are, independently selected from




and n=1 to 4.

26. (NEW CLAIM) The method of Claim 25, wherein the compound is α -thalidomide having the following formula;




27. (NEW CLAIM) The method of Claim 25, wherein the compound is EM-138 having the following formula;



28. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-aminothalidomide having the following formula;



29. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxythalidomide, having the following formula;



30. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxy-EM-138, having the following formula;




31. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxy-EM-27, having the following formula;



32. (NEW CLAIM) The method of Claim 25, wherein the compound is 3-hydroxyphthalimido-glutarmic acid, having the following formula;



33. (NEW CLAIM) The method of Claim 25, wherein the compound is EM-12, having the following formula;



34. (NEW CLAIM) The method of Claim 25, wherein the compound is a thalidomide metabolite or hydrolysis product.

35. (NEW CLAIM) The method of Claim 25, wherein the composition further comprises an epoxide hydrolase inhibitor.

36. (NEW CLAIM) The method of Claim 25, wherein the undesired angiogenesis is associated with retinal neovascularization.

37. (NEW CLAIM) The method of Claim 25, wherein the undesired angiogenesis is associated with choroidal neovascularization.

38. (NEW CLAIM) The method of Claim 25 wherein the undesired angiogenesis is associated with diabetic retinopathy.